title: Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease.
abstract: This study describes issues related to the safety and tolerability of fetal striatal neural allografts as assessed in five patients with Huntington's disease. Huntington's disease (HD) is characterized by motor, cognitive, and behavioral disturbances. The latter include psychological disturbances and, as a consequence, we took particular care to analyze behavioral changes, in addition to the usual "safety" follow-up. We conducted multidisciplinary follow-up at least 2 years before and 1 year after grafting. Psychological care extended to close relatives. The grafting procedure itself was altogether safe and uneventful, and there were no apparent clinical deleterious effects for 1 year. The immunosuppressive treatment, however, was complicated by various problems (irregular compliance, errors of handling, side effects). Direct psychological consequences of the transplantation procedure were rare and not worrisome, although mood alteration requiring treatment was observed in one patient. Indirectly, however, the procedure required patients and relatives to accept constraints that tended to complicate familial situations already marred by aggressivity and depression. All patients and close relatives expressed major expectations, in spite of our strong and repeated cautioning. It is clearly important to be aware of these particular conditions since they may eventually translate into psychological difficulties in coping with the long-term clinical outcome of the procedure, if not beneficial. Despite an overall good tolerance, therefore, this follow-up calls for caution regarding the involvement of HD patients in experimental surgical protocols.
authors.affiliation: Faculté de Médecine, INSERM U. 421/IM3, Créteil, 94010, France.
authors.forename: A
authors.initials: A
authors.lastname: Bachoud-Lévi
authors.forename: C
authors.initials: C
authors.lastname: Bourdet
authors.forename: P
authors.initials: P
authors.lastname: Brugières
authors.forename: J P
authors.initials: JP
authors.lastname: Nguyen
authors.forename: T
authors.initials: T
authors.lastname: Grandmougin
authors.forename: B
authors.initials: B
authors.lastname: Haddad
authors.forename: R
authors.initials: R
authors.lastname: Jény
authors.forename: P
authors.initials: P
authors.lastname: Bartolomeo
authors.forename: M F
authors.initials: MF
authors.lastname: Boissé
authors.forename: G D
authors.initials: GD
authors.lastname: Barba
authors.forename: J D
authors.initials: JD
authors.lastname: Degos
authors.forename: A M
authors.initials: AM
authors.lastname: Ergis
authors.forename: J P
authors.initials: JP
authors.lastname: Lefaucheur
authors.forename: F
authors.initials: F
authors.lastname: Lisovoski
authors.forename: E
authors.initials: E
authors.lastname: Pailhous
authors.forename: P
authors.initials: P
authors.lastname: Rémy
authors.forename: S
authors.initials: S
authors.lastname: Palfi
authors.forename: G L
authors.initials: GL
authors.lastname: Defer
authors.forename: P
authors.initials: P
authors.lastname: Cesaro
authors.forename: P
authors.initials: P
authors.lastname: Hantraye
authors.forename: M
authors.initials: M
authors.lastname: Peschanski
mesh_terms: D000328:Adult; D016380:Brain Tissue Transplantation; D003071:Cognition; D003342:Corpus Striatum / Q000601:surgery*; D016572:Cyclosporine / Q000009:adverse effects; D005190:Family; D005260:Female; D016332:Fetal Tissue Transplantation; D005500:Follow-Up Studies; D006801:Humans; D006816:Huntington Disease / Q000473:pathology / Q000523:psychology / Q000601:surgery*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011182:Postoperative Care; D011300:Preoperative Care; D012449:Safety; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine